Hidradenitis suppurativa is a chronic debilitating systemic skin disease, resulting in painful inflammation and follicles in the armpit, groin, and genitalia regions. It affects 4% of the population, and the disease onset occurs in the second decade of a patient’s life with 2:3 of the patients being women.
The patient is diagnosed by a physical examination and can be treated with topical, oral or intravenous antibiotic treatments. The treatments provide temporary relief, and some patients undergo surgical treatment to reduce the pain. Recently adalimumab (TNF-a inhibitor) has been approved for moderate to severe hidradenitis suppurativa, while no biological treatments are available for patients with mild disease.
Hidradenitis Suppurativa is characterized as a dermatological disease where the tissue architecture is being remodeled. The main component of the skin are collagens, which are remodeled as a part of the normal homeostasis of the skin. In hidradenitis suppurativa, there is an imbalance of tissue build-up and tissue breakdown, resulting in a net degradation of the tissue. Nordic Bioscience's biomarkers can quantify skin tissue turnover directly in a serum sample and serve as a liquid biopsy.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
